Schizophrenia News and Research

Latest Schizophrenia News and Research

MAGI genes play a role in psychiatric disease

These findings are not about the classic story of gift-giving, although the MAGI genes (officially named membrane associated guanylate kinase, WW and PDZ domain containing proteins) do influence brain function in important ways.

11 May 2012

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that analysis of U.S. longitudinal patient-level claims data reveals the use of Bristol-Myers Squibb's oral Abilify as a first-line therapy for newly diagnosed schizophrenia patients continues to grow.

10 May 2012

Genes determine brain size: Global brain study

In the world's largest study of the human brain, involving more than 200 scientists worldwide, researchers have found that genes that affect brain size may play a part in intelligence and memory function. The study was put together by combining brain scans and genetic data from 21,000 people worldwide.

10 May 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

UAB’s First Episode Schizophrenia Clinic rapidly treats patients with new diagnosis

Like the "golden hour" of trauma care that increases the odds of a person's survival, some clinicians are now applying that philosophy to the treatment of schizophrenia, one of the most puzzling mental health disorders.

10 May 2012

Study shows effects of psychotropic drug treatment on brain morphology

It is increasingly recognized that chronic psychotropic drug treatment may lead to structural remodeling of the brain. Indeed, clinical studies in humans present an intriguing picture: antipsychotics, used for the treatment of schizophrenia and psychosis, may contribute to cortical gray matter loss in patients, whereas lithium, used for the treatment of bipolar disorder and mania, may preserve gray matter in patients.

9 May 2012

Antidepressives reduce risk of suicides in schizophrenic patients

Antidepressive drugs reduce the mortality rate of schizophrenic patients, while treatment with bensodiazepines greatly increases it, especially as regards suicide. Giving several antipsychotics simultaneously, however, seems to have no effect at all. This according to a new study examining different drug combinations administered to patients with schizophrenia.

9 May 2012

ACADIA first quarter net loss increases to $6.2 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2012.

9 May 2012

Study shows how adolescent cannabis use can cause schizophrenia

New research from the Royal College of Surgeons in Ireland (RCSI) published in Nature's Neuropsychopharmacology has shown physical changes to exist in specific brain areas implicated in schizophrenia following the use of cannabis during adolescence. The research has shown how cannabis use during adolescence can interact with a gene, called the COMT gene, to cause physical changes in the brain.

9 May 2012

Chemically altered proteins may be key to understanding memories

Having a fat head may not be a bad thing, according to new findings at The Johns Hopkins University. As reported in the February 9 issue of Neuron, researchers have made a significant discovery as to how adding fat molecules to proteins can influence the brain circuitry controlling cognitive function, including learning and memory.

8 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression (PREVAIL 1 and PREVAIL 2; PRogram to EValuate the Antidepressant Impact of Lurasidone).

7 May 2012

Automated way to record electrical activity inside neurons in the living brain

Gaining access to the inner workings of a neuron in the living brain offers a wealth of useful information: its patterns of electrical activity, its shape, even a profile of which genes are turned on at a given moment. However, achieving this entry is such a painstaking task that it is considered an art form; it is so difficult to learn that only a small number of labs in the world practice it.

7 May 2012

Brain networks may avoid traffic jams by communicating on different frequencies

Brain networks may avoid traffic jams at their busiest intersections by communicating on different frequencies, researchers at Washington University School of Medicine in St. Louis, the University Medical Center at Hamburg-Eppendorf and the University of T-bingen have learned.

7 May 2012

FDA issues Complete Response Letter to Alexza’s ADASUVE NDA

Alexza Pharmaceuticals, Inc. announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ADASUVE (loxapine) inhalation powder, 5 mg and 10 mg.

4 May 2012

Scientists address mental health and well-being at Association for Psychological Science's annual meeting

Are our existing treatments for mental health issues working? Can we design new and better approaches to intervention? Can we even tell which factors promote mental health? Clinical psychological scientists will be addressing these and many other questions related to mental health and well-being at the Association for Psychological Science's 24th annual meeting in Chicago, May 24-27, 2012.

3 May 2012

Dopamine linked to willingness to work for a monetary reward

A new brain imaging study has shown that an individual’s willingness to work hard to earn money is strongly influenced by the chemistry in three specific areas of the brain. Researchers claim that this could have important implications for the treatment of attention-deficit disorder, depression, schizophrenia and other forms of mental illness characterized by decreased motivation.

3 May 2012

Parental history of psychosis linked with increased risk of epilepsy in offspring

Although the two disorders may seem dissimilar, epilepsy and psychosis are associated. Individuals with epilepsy are more likely to have schizophrenia, and a family history of epilepsy is a risk factor for psychosis. It is not known whether the converse is true, i.e., whether a family history of psychosis is a risk factor for epilepsy.

3 May 2012

Roundup: Mass. premium increases muted; Iowa cuts payment to charity after fraud probe; Ga. asks EMS providers to save scarce drugs

State regulators on Monday approved third-quarter health insurance rates that will raise premiums an average of just 1.2 percent in the market serving small businesses and individuals, continuing a trend of more modest increases seen over the past three quarters. And several carriers, including Tufts Health Plan of Watertown and Fallon Community Health Plan, based in Worcester, will reduce their rates -- a rarity in Massachusetts health care -- according to data from the state Division of Insurance.

2 May 2012

Viewpoints: Entitlement 'train wrecks' approaching; Collecting for health bills at the hospital

The evidence has been clear for a long time now regarding the future of those twin financial train wrecks known as Social Security and Medicare. We have known for decades that without significant reform both are on a path toward insolvency.

30 Apr 2012

Schizophrenia News and Research

Latest Schizophrenia News and Research

MAGI genes play a role in psychiatric disease

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

Genes determine brain size: Global brain study

Sunovion announces results from LATUDA open-label study for schizophrenia

UAB’s First Episode Schizophrenia Clinic rapidly treats patients with new diagnosis

Study shows effects of psychotropic drug treatment on brain morphology

Antidepressives reduce risk of suicides in schizophrenic patients

ACADIA first quarter net loss increases to $6.2 million

Study shows how adolescent cannabis use can cause schizophrenia

Chemically altered proteins may be key to understanding memories

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Positive results from Dainippon Sumitomo Pharma's LATUDA trials for bipolar I depression

Automated way to record electrical activity inside neurons in the living brain

Brain networks may avoid traffic jams by communicating on different frequencies

FDA issues Complete Response Letter to Alexza’s ADASUVE NDA

Scientists address mental health and well-being at Association for Psychological Science's annual meeting

Dopamine linked to willingness to work for a monetary reward

Parental history of psychosis linked with increased risk of epilepsy in offspring

Roundup: Mass. premium increases muted; Iowa cuts payment to charity after fraud probe; Ga. asks EMS providers to save scarce drugs

Viewpoints: Entitlement 'train wrecks' approaching; Collecting for health bills at the hospital

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Schizophrenia News and Research

Latest Schizophrenia News and Research

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Newsletters you may be interested in